Medical specialties

MS Society of Canada Counts on Canadians for Nationwide Support in Fight to End MS

Retrieved on: 
Tuesday, June 30, 2020
Multiple Sclerosis Society of Canada, Medical specialties, Health, Multiple sclerosis, National Multiple Sclerosis Society, National Capital Chapter, Medicine, MS Readathon

For the Multiple Sclerosis (MS) Society of Canada , this unity highlights the work of those who have come together to support Canadians living with MS. Canada has one of the highest rates of MS in the world.

Key Points: 
  • For the Multiple Sclerosis (MS) Society of Canada , this unity highlights the work of those who have come together to support Canadians living with MS. Canada has one of the highest rates of MS in the world.
  • The need for Canadians to stand up to help ensure the MS Society of Canada can continue to support Canadians affected by MS is mission critical, says Pamela Valentine, president and CEO, MS Society of Canada.
  • Through online events and initiatives like #WeChallengeMS , Virtual MS Walk and the upcoming Virtual MS Bike , the MS Society has been able to continue providingessential support, advocacy and resources for Canadians living with MS and their families.
  • Typically, the MS Society of Canada and the MS community come together each summer to hold a series of MS fundraising events across the country, in an effort to help bring Canada closer to a world free of MS.

A Data Treasure for Gait Analysis: St. Pölten UAS and Insurance Institution AUVA Open Database for Research

Retrieved on: 
Tuesday, June 30, 2020
Medical specialties, Medicine, Biometrics, Gait analysis, Rehabilitation medicine, Terrestrial locomotion

The more data we have, the better the results," explains Brian Horsak, head of the research focus Motor Rehabilitation at the St. Plten UAS.

Key Points: 
  • The more data we have, the better the results," explains Brian Horsak, head of the research focus Motor Rehabilitation at the St. Plten UAS.
  • In order to facilitate research, therapy and diagnosis, Brian Horsak and his colleagues at the St. Plten UAS and the AUVA have now published one of the biggest data records worldwide on this topic in anonymised form.
  • The data come from several years of clinical gait analysis practice and can be used to improve analysis procedures and models.
  • With the Digital Health Lab, the UAS has one of the most modern research labs in Austria in these fields.

A Data Treasure for Gait Analysis: St. Pölten UAS and Insurance Institution AUVA Open Database for Research

Retrieved on: 
Tuesday, June 30, 2020
Medical specialties, Terrestrial locomotion, Medicine, Walking, Clinical medicine, Biometrics, Gait analysis, Rehabilitation medicine, Gait

The St. Plten UAS and the Austrian general accident insurance institution AUVA have made one of the biggest data records for automated gait analysis worldwide openly accessible.

Key Points: 
  • The St. Plten UAS and the Austrian general accident insurance institution AUVA have made one of the biggest data records for automated gait analysis worldwide openly accessible.
  • Researchers are free to use the data in order to improve automated gait analysis with the help of methods such as machine learning.
  • ST. PLTEN, Austria, June 30, 2020 /PRNewswire/ --"Gait analysis provides a huge amount of data.
  • The more data we have, the better the results," explains Brian Horsak, head of the research focus Motor Rehabilitation at the St. Plten UAS.

Release of Initial Attana Virus Analytics-AVA Testing Protocols

Retrieved on: 
Tuesday, June 30, 2020
Medical specialties, Medicine, Health, Immunologic tests, Pharmaceutical industry, Validity, Antibody, Glycoproteins, Immunology, ELISA, Validation, Communication protocol

STOCKHOLM, June 30, 2020 /PRNewswire/ -- Attana has today released the initial technical protocols for AVA Antibody Testing and will make these available to all existing Attana customers.

Key Points: 
  • STOCKHOLM, June 30, 2020 /PRNewswire/ -- Attana has today released the initial technical protocols for AVA Antibody Testing and will make these available to all existing Attana customers.
  • By optimizing the testing procedures, two protocols have now successfully been established and preparations are being made for the scientific publication of corresponding technical notes.
  • The AVA Antibody-Testing protocols are comprised of two distinct components: (1) AVA AB Validation and (2) AVA AB Assurance.
  • The release of these initial protocols enables any Attana Cell 200 instrument to be employed in COVID-19 antibody testing with minor modifications and the addition of the necessary Attana consumables and reagents.

Release of Initial Attana Virus Analytics-AVA Testing Protocols

Retrieved on: 
Tuesday, June 30, 2020
Medical specialties, Medicine, Health, Immunologic tests, Pharmaceutical industry, Validity, Antibody, Glycoproteins, Immunology, ELISA, Validation, Communication protocol

STOCKHOLM, June 30, 2020 /PRNewswire/ -- Attana has today released the initial technical protocols for AVA Antibody Testing and will make these available to all existing Attana customers.

Key Points: 
  • STOCKHOLM, June 30, 2020 /PRNewswire/ -- Attana has today released the initial technical protocols for AVA Antibody Testing and will make these available to all existing Attana customers.
  • By optimizing the testing procedures, two protocols have now successfully been established and preparations are being made for the scientific publication of corresponding technical notes.
  • The AVA Antibody-Testing protocols are comprised of two distinct components: (1) AVA AB Validation and (2) AVA AB Assurance.
  • The release of these initial protocols enables any Attana Cell 200 instrument to be employed in COVID-19 antibody testing with minor modifications and the addition of the necessary Attana consumables and reagents.

Health Canada Allows COVID-19 Patients with Respiratory Failure to Be Given NuvOx Pharma's Oxygen Therapeutic in Phase IIa Clinical Trial

Retrieved on: 
Tuesday, June 30, 2020
Health, Infectious diseases, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Medicine, Intensive care medicine, Respiratory diseases, Medical emergencies, Branches of biology, Respiratory distress syndrome, Acute respiratory distress syndrome, Hypercapnia, Respiratory failure

NuvOx Pharma, a Tucson-based biotechnology company developing NanO2 emulsion for oxygen delivery, has received a No Objection Letter from Health Canada to proceed with a Phase IIa clinical trial of NanO2 in COVID-19 subjects with acute hypoxic respiratory failure (AHRF).

Key Points: 
  • NuvOx Pharma, a Tucson-based biotechnology company developing NanO2 emulsion for oxygen delivery, has received a No Objection Letter from Health Canada to proceed with a Phase IIa clinical trial of NanO2 in COVID-19 subjects with acute hypoxic respiratory failure (AHRF).
  • Some patients with AHRF can progress to a more severe form of the disease called acute respiratory distress syndrome (ARDS).
  • Because of this, we designed a clinical trial to study NanO2 in COVID-19 patients.
  • The trial will determine if NanO2 improves clinical outcomes in COVID-19 subjects with acute hypoxic respiratory failure.

COVID-19 ICUs Life Support Equipment Market Growth. Up To $30 Billion per Annum

Retrieved on: 
Monday, June 29, 2020
Medicine, Medical specialties, Respiratory therapy, Health care, Medical ventilator, Mechanical ventilation

/PRNewswire/ --According to the report, the booming COVID-19 ICUs life support equipment market size will reach up to $30 Billion per Annum and the COVID-19 related ICU 2020-2024 cumulative market share will be 4.5%-8.3 % of the total COVID-19 pandemic mitigation products market.

Key Points: 
  • /PRNewswire/ --According to the report, the booming COVID-19 ICUs life support equipment market size will reach up to $30 Billion per Annum and the COVID-19 related ICU 2020-2024 cumulative market share will be 4.5%-8.3 % of the total COVID-19 pandemic mitigation products market.
  • The COVID-19 pandemic has led to acute deficiencies of essentialICU equipment and services from invasive mechanical ventilators and noninvasive ventilators to COVID-19 homecare equipment and portable ventilators.
  • Last but not least, governments in anticipation of the next pandemic surge will aggressively stockpile a strategic storage of non-invasive ventilators.
  • The COVID-19 Pandemic Mitigation Products Market - 2020-2024 report includes 54 sub-reports including the following nine COVID-19 related ICU sub-reports:

COVID-19 Spurs Huge Virtual Congressional Contact With Kidney Patients And Top Doctors

Retrieved on: 
Monday, June 29, 2020
Medical specialties, Medicine, Clinical medicine, Kidney diseases, Organ failure, RTT, Kidney transplantation, Kidney disease, Chronic kidney disease, Organ transplantation, Nephrology

Prior to the congressional visits, the U.S. Centers for Disease Control and Prevention (CDC) listed chronic kidney disease (CKD) patients, patients with organ transplants, and those on immunosuppressive medications at high-risk for COVID-19.

Key Points: 
  • Prior to the congressional visits, the U.S. Centers for Disease Control and Prevention (CDC) listed chronic kidney disease (CKD) patients, patients with organ transplants, and those on immunosuppressive medications at high-risk for COVID-19.
  • Patients and renal professionals discussed key issues including the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (S. 3353 / H.R.
  • Blaser is a highly respected kidney legislation expert and a recipient of the AAKP President's Award for his efforts on behalf of kidney patients and their families.
  • About the American Association of Kidney Patients (AAKP): AAKP is among thestrongest advocates for kidney patient consumer care choice and treatment innovation.

Halozyme Announces Roche Receives FDA Approval For Phesgo™ (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Breast Cancer

Retrieved on: 
Monday, June 29, 2020
Life sciences, Medical specialties, Biology, Biotechnology, Immunology, Monoclonal antibodies, Biopharmaceutical, Pharmaceutical industry, Pharmacy, Antibody, Halozyme, Inc.

This is the first time a product has been approved combining two monoclonal antibodies that can be administered by a single subcutaneous injection utilizing Halozyme's ENHANZE technology.

Key Points: 
  • This is the first time a product has been approved combining two monoclonal antibodies that can be administered by a single subcutaneous injection utilizing Halozyme's ENHANZE technology.
  • Phesgo is the second product to receive FDA approval this year, and the first demonstrating the ability to combine two monoclonal antibodies, utilizing our ENHANZE technology."
  • (2,3) Phesgo can be administered by a healthcare professional in a treatment center or at a patient's home.
  • Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Intercept Pharmaceuticals, Inc. (ICPT) on Behalf of Investors

Retrieved on: 
Monday, June 29, 2020
Legal, Professional services, Medical specialties, Medicine, Hepatitis, Health, Cholanes, Obeticholic acid, Intercept Pharmaceuticals, RTT, Steatohepatitis, Non-alcoholic fatty liver disease, Food and Drug Administration, Intercept

Law Offices of Howard G. Smith announces an investigation on behalf of Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ: ICPT ) investors concerning the Company and its officers possible violations of federal securities laws.

Key Points: 
  • Law Offices of Howard G. Smith announces an investigation on behalf of Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ: ICPT ) investors concerning the Company and its officers possible violations of federal securities laws.
  • On June 29, 2020, Intercept disclosed receipt of a complete response letter ("CRL") from the U.S. Food and Drug Administration ("FDA") regarding the New Drug Application for obeticholic acid ("OCA") for the treatment of fibrosis due to nonalcoholic steatohepatitis ("NASH").
  • On this news, the Company's share price fell as much as $29.78, or 38%, during intraday trading on June 29, 2020.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.